Cal Apatite with Magnesium
Natural health product licensed in Canada
- Other names
- Cal Apatite Bone Builder with Magnesium
- Licence holder
- Metagenics Inc.
- NPN or DIN-HM
- 80028704
- Status
- Inactive licence
- Licence date
- 19 December 2011
- Revision date
- 16 April 2012
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine D: up to 15 µg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 5 µg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Magnésium: up to 300 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (250 mg a day). Pour ce nutriment, le repère de l'EFSA ne porte que sur les apports ajoutés (compléments, aliments enrichis), pas sur ce qu'apporte l'alimentation courante.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Magnésium Source : Citrate de magnésium | 100 mg | 300,000 µg |
| Magnésium Source : Aspartate de magnésium | 100 mg | 300,000 µg |
| Magnésium Source : Bisglycinate de magnésium | 100 mg | 300,000 µg |
| Calcium Source : Microcrystalline hydroxyapatite | 200 mg | 600,000 µg |
| Calcium Source : Phosphate de calcium, dibasique | 200 mg | 600,000 µg |
| Vitamine D Source : Cholécalciférol | 5 mcg | 15 µg |
Non-medicinal ingredients
Carraghénine, Acide stéarique, cellulose, Silice, Croscarmellose de sodium, Eau désionisée, PEG (polyéthylèneglycol), Glycolate d'amidon sodique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adolescentes | minimum: 9 years ; maximum: 18 years | 3 Comprimé | 1 Tous les jours |
| Adultes | Not specified | 3 Comprimé | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Adequate calcium and vitamin D, as part of a healthy diet, help prevent bone loss/osteoporosis. Helps in the development and maintenance of bones and teeth (especially in adolescence and young adulthood).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80028704
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2012. Photograph the packaging to check whether it has changed. Photograph the packaging